Cargando…
Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis
BACKGROUND & AIMS: Prognostic tests are critical in the management of patients with cirrhosis and ascites. Biological tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spectroscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more re...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636102/ https://www.ncbi.nlm.nih.gov/pubmed/29020046 http://dx.doi.org/10.1371/journal.pone.0185997 |
_version_ | 1783270384932487168 |
---|---|
author | Le Corvec, Maëna Jezequel, Caroline Monbet, Valérie Fatih, Nadia Charpentier, Frédéric Tariel, Hugues Boussard-Plédel, Catherine Bureau, Bruno Loréal, Olivier Sire, Olivier Bardou-Jacquet, Edouard |
author_facet | Le Corvec, Maëna Jezequel, Caroline Monbet, Valérie Fatih, Nadia Charpentier, Frédéric Tariel, Hugues Boussard-Plédel, Catherine Bureau, Bruno Loréal, Olivier Sire, Olivier Bardou-Jacquet, Edouard |
author_sort | Le Corvec, Maëna |
collection | PubMed |
description | BACKGROUND & AIMS: Prognostic tests are critical in the management of patients with cirrhosis and ascites. Biological tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spectroscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more relevant information by measuring a wider range of metabolic parameters in serum. Here we present the accuracy of a MIR-FEWS based predictive model for the prognosis of 6 months survival in patients with ascites and cirrhosis. METHODS: Patients with ascites were prospectively included and followed up for 6 months. MIR-FEWS spectra were measured in serum samples. The most informative spectral variables obtained by MIR-FEWS were selected by FADA algorithm and then used to build the MIR model. Accuracy of this model was assessed by ROC curves and 90%/10% Monte Carlo cross-validation. MIR model accuracy for 6 months survival was compared to that of the Child-Pugh and MELD scores. RESULTS: 119 patients were included. The mean age was 57.36±13.70, the MELD score was 16.32±6.26, and the Child-Pugh score was 9.5±1.83. During follow-up, 23 patients died (20%). The MIR model had an AUROC for 6 months mortality of 0.90 (CI95: 0.88–0.91), the MELD 0.77 (CI95: 0.66–0.89) and Child-Pugh 0.76 (CI95: 0.66–0.88). MELD and Child-Pugh AUROCs were significantly lower than that of the MIR model (p = 0.02 and p = 0.02 respectively). Multivariate logistic regression analysis showed that MELD (p<0.05, OR:0.86;CI95:0.76–0.97), Beta blockers (p = 0.036;OR:0.20;CI95:0.04–0.90), and the MIR model (p<0.001; OR:0.50; CI95:0.37–0.66), were significantly associated with 6 months mortality. CONCLUSIONS: In this pilot study MIR-FEWS more accurately assess the 6-month prognosis of patients with ascites and cirrhosis than the MELD or Child-Pugh scores. These promising results, if confirmed by a larger study, suggest that mid infrared spectroscopy could be helpful in the management of these patients. |
format | Online Article Text |
id | pubmed-5636102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56361022017-10-30 Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis Le Corvec, Maëna Jezequel, Caroline Monbet, Valérie Fatih, Nadia Charpentier, Frédéric Tariel, Hugues Boussard-Plédel, Catherine Bureau, Bruno Loréal, Olivier Sire, Olivier Bardou-Jacquet, Edouard PLoS One Research Article BACKGROUND & AIMS: Prognostic tests are critical in the management of patients with cirrhosis and ascites. Biological tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spectroscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more relevant information by measuring a wider range of metabolic parameters in serum. Here we present the accuracy of a MIR-FEWS based predictive model for the prognosis of 6 months survival in patients with ascites and cirrhosis. METHODS: Patients with ascites were prospectively included and followed up for 6 months. MIR-FEWS spectra were measured in serum samples. The most informative spectral variables obtained by MIR-FEWS were selected by FADA algorithm and then used to build the MIR model. Accuracy of this model was assessed by ROC curves and 90%/10% Monte Carlo cross-validation. MIR model accuracy for 6 months survival was compared to that of the Child-Pugh and MELD scores. RESULTS: 119 patients were included. The mean age was 57.36±13.70, the MELD score was 16.32±6.26, and the Child-Pugh score was 9.5±1.83. During follow-up, 23 patients died (20%). The MIR model had an AUROC for 6 months mortality of 0.90 (CI95: 0.88–0.91), the MELD 0.77 (CI95: 0.66–0.89) and Child-Pugh 0.76 (CI95: 0.66–0.88). MELD and Child-Pugh AUROCs were significantly lower than that of the MIR model (p = 0.02 and p = 0.02 respectively). Multivariate logistic regression analysis showed that MELD (p<0.05, OR:0.86;CI95:0.76–0.97), Beta blockers (p = 0.036;OR:0.20;CI95:0.04–0.90), and the MIR model (p<0.001; OR:0.50; CI95:0.37–0.66), were significantly associated with 6 months mortality. CONCLUSIONS: In this pilot study MIR-FEWS more accurately assess the 6-month prognosis of patients with ascites and cirrhosis than the MELD or Child-Pugh scores. These promising results, if confirmed by a larger study, suggest that mid infrared spectroscopy could be helpful in the management of these patients. Public Library of Science 2017-10-11 /pmc/articles/PMC5636102/ /pubmed/29020046 http://dx.doi.org/10.1371/journal.pone.0185997 Text en © 2017 Le Corvec et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Le Corvec, Maëna Jezequel, Caroline Monbet, Valérie Fatih, Nadia Charpentier, Frédéric Tariel, Hugues Boussard-Plédel, Catherine Bureau, Bruno Loréal, Olivier Sire, Olivier Bardou-Jacquet, Edouard Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis |
title | Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis |
title_full | Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis |
title_fullStr | Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis |
title_full_unstemmed | Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis |
title_short | Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis |
title_sort | mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636102/ https://www.ncbi.nlm.nih.gov/pubmed/29020046 http://dx.doi.org/10.1371/journal.pone.0185997 |
work_keys_str_mv | AT lecorvecmaena midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT jezequelcaroline midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT monbetvalerie midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT fatihnadia midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT charpentierfrederic midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT tarielhugues midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT boussardpledelcatherine midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT bureaubruno midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT lorealolivier midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT sireolivier midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis AT bardoujacquetedouard midinfraredspectroscopyofserumapromisingnoninvasivemethodtoassessprognosisinpatientswithascitesandcirrhosis |